These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 36521078)
21. Long-Term Follow-Up of the Intergroup Exemestane Study. Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729 [TBL] [Abstract][Full Text] [Related]
22. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Colleoni M; Munzone E Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant endocrine therapy for premenopausal women: Type and duration. Francis PA Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis. Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567 [TBL] [Abstract][Full Text] [Related]
25. Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer. Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918 [TBL] [Abstract][Full Text] [Related]
26. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
27. Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. Kubo M Chin Clin Oncol; 2020 Jun; 9(3):33. PubMed ID: 32527118 [TBL] [Abstract][Full Text] [Related]
28. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L; Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227 [TBL] [Abstract][Full Text] [Related]
29. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Goel S; Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study. Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728 [TBL] [Abstract][Full Text] [Related]
31. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS; Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763 [TBL] [Abstract][Full Text] [Related]
32. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis. Jiang M; Chen W; Hu Y; Chen C; Li H Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958 [TBL] [Abstract][Full Text] [Related]
34. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650 [TBL] [Abstract][Full Text] [Related]
35. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial. Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995 [TBL] [Abstract][Full Text] [Related]
36. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. Kim HA; Lee JW; Nam SJ; Park BW; Im SA; Lee ES; Jung YS; Yoon JH; Kang SS; Lee SJ; Park KH; Jeong J; Cho SH; Kim SY; Kim LS; Moon BI; Lee MH; Kim TH; Park C; Jung SH; Gwak G; Kim J; Kang SH; Jin YW; Kim HJ; Han SH; Han W; Hur MH; Noh WC; J Clin Oncol; 2020 Feb; 38(5):434-443. PubMed ID: 31518174 [TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Mathew A; Davidson NE Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743 [TBL] [Abstract][Full Text] [Related]
38. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662 [TBL] [Abstract][Full Text] [Related]
39. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]